A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimers Disease

Interventions

DRUG: Trontinemab
OTHER: Placebo

Sponsor

Hoffmann-La Roche